Top Page
ImExHS Limited
(Sydney:IME)
ImExHS Limited (IME) vs. iShares MSCI Australia ETF (EWA)
ImExHS Limited Business Overview & Revenue Model
ImExHS Limited Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.97M | 26.57M | 19.67M | 17.12M | 13.37M |
| Gross Profit | 8.31M | 11.03M | 3.50M | 3.52M | 5.22M |
| EBITDA | 1.52M | 45.58K | -1.26M | -744.21K | -3.00M |
| Net Income | -2.88M | -2.63M | -4.19M | -3.04M | -4.70M |
Balance Sheet | |||||
| Total Assets | 23.73M | 21.81M | 22.65M | 20.99M | 25.01M |
| Cash, Cash Equivalents and Short-Term Investments | 3.30M | 2.07M | 2.36M | 1.91M | 4.19M |
| Total Debt | 566.32K | 1.19M | 1.29M | 1.12M | 2.40M |
| Total Liabilities | 7.86M | 7.33M | 6.67M | 5.09M | 8.36M |
| Stockholders Equity | 15.87M | 14.47M | 15.98M | 15.90M | 16.65M |
Cash Flow | |||||
| Free Cash Flow | 244.16K | -1.69M | 414.59K | -4.23M | -5.53M |
| Operating Cash Flow | 564.71K | -634.68K | 2.61M | -2.20M | -2.97M |
| Investing Cash Flow | -1.19M | -765.91K | -2.13M | -2.22M | -3.39M |
| Financing Cash Flow | 1.68M | 1.18M | -98.61K | 2.25M | -161.78K |
ImExHS Limited Technical Analysis
ImExHS Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$21.35M | -7.11 | -19.01% | ― | 6.77% | -8.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$19.56M | 3.95 | 7.57% | ― | 28.91% | -1050.00% | |
45 Neutral | AU$31.35M | -3.13 | -1009.84% | ― | 25.98% | 22.10% | |
44 Neutral | AU$42.14M | -5.70 | -14.19% | ― | 3.61% | -17.03% | |
43 Neutral | AU$64.72M | -6.64 | -59.96% | ― | ― | ― |
ImExHS Limited Corporate Events
ImExHS Limited has confirmed the lodgement of its corporate governance statement for the financial year ended 31 December 2025, making it accessible via its investor centre website in accordance with ASX Listing Rule 4.10.3. The company has also submitted a completed Appendix 4G, outlining how it complies with the ASX Corporate Governance Council’s principles and recommendations, including the existence of a board charter, director appointment checks and written agreements for directors and executives.
These filings indicate that ImExHS is maintaining compliance with its ongoing ASX governance disclosure requirements and providing transparency around its board roles, oversight structures and appointment processes. For investors and other stakeholders, the updated governance statement and Appendix 4G serve as a guide to assessing the robustness of the company’s governance framework and its adherence to recognised best-practice standards.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has released its updated Corporate Governance Statement as at 27 February 2026, outlining the extent of its compliance with the ASX Corporate Governance Council’s fourth edition principles and recommendations. The document details which recommendations are followed, where deviations occur, and what alternative practices are in place, reinforcing transparency and providing stakeholders with clarity on governance structures and oversight.
The statement emphasises the board’s responsibility for strategic direction, major financial decisions, executive appointments, and approval of key financial reports, while delegating daily operations to the managing director and management team. By formalising these roles and maintaining a clear governance framework, ImExHS aims to strengthen board oversight, risk management and reporting, supporting confidence among shareholders and aligning its practices with market expectations for listed entities.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited outlined its FY25 positioning as a unified company with two complementary business lines dedicated to democratizing access to medical imaging expertise. It highlighted its dual focus on medical imaging software and Colombia-based radiology services, signaling an integrated model intended to enhance clinical workflows and expand imaging accessibility across its key markets.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS reported full-year 2025 revenue of $29.0 million, up 10% on the prior year and above guidance, with underlying EBITDA tripling to $1.6 million as recurring revenue, annualised recurring revenue and cash all improved while debt fell. The company processed 8.2 million studies with near-perfect uptime, advanced deployment of its Aquila+ platform, expanded its partner programme, turned around its RIMAB radiology unit and signalled a strategic focus on accelerating higher-margin software growth while pursuing only strongly profitable radiology contracts amid healthcare budget pressures.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited reported a 9.5% increase in revenue to $28.97 million for the year ended 31 December 2025, while its net loss after tax widened slightly to $2.88 million compared with $2.63 million a year earlier. Despite the ongoing losses and the absence of dividends, the total comprehensive loss narrowed significantly to $1.51 million, and net tangible assets per share improved to 17.10 cents from 13.84 cents, suggesting a strengthening balance sheet even as auditors highlighted going-concern considerations.
The board noted that no dividends were paid or declared for the period, reflecting the company’s continued focus on reinvestment and financial consolidation. The audited accounts received an unmodified opinion with an emphasis on going concern, underlining both the progress in asset backing and the need for sustained operational improvement to reach profitability.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has scheduled the release of its FY25 financial results for 27 February 2026, covering the year ended 31 December 2025. The company will follow this with an investor presentation led by CEO and Co-Founder Dr German Arango and CFO Reena Minhas on 3 March 2026 at 11:00am AEST.
The results briefing, accessible via pre-registration, is positioned as a key communication touchpoint for shareholders and stakeholders to gain insight into IMEXHS’s recent performance. It also reinforces the company’s ongoing investor engagement as it continues to scale its cloud-based medical imaging and radiology services platform across multiple international markets.
The most recent analyst rating on (AU:IME) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited reported unaudited full-year 2025 results at the top end of its guidance, with revenue rising 10% to $29.0 million and underlying EBITDA more than tripling to $1.6 million, supported by a strong fourth quarter and a 16% increase in annualised recurring revenue to $34.8 million. Recurring revenue reached $28.5 million on a like-for-like basis, software revenue grew 25% in the fourth quarter excluding one-offs, and the company secured new and renewed enterprise contracts, public-sector tenders in Colombia and Mexico, and expanding partner programme contributions, while improving cash and cutting debt; management highlighted that these gains were achieved despite a volatile Colombian healthcare and FX environment, underscoring stronger execution and momentum into FY26.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.42 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
IMEXHS Limited has disclosed a change in the interests of director Douglas Flynn, detailing an internal restructuring of his shareholdings between direct and indirect holdings. Flynn disposed of 160,573 fully paid ordinary shares held directly, in an off-market sale to his superannuation vehicle, DR & LC Flynn Nominees Pty Limited
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has disclosed a change in director Damian Banks’ relevant interests in the company’s securities, reporting an internal restructuring of his holdings between direct and indirect ownership. Banks sold 80,287 fully paid ordinary shares off-market from his personal holding to Damisuper Pty Ltd, a superannuation fund vehicle for which he is a director and beneficiary, for approximately $31,312, leaving him with 37,356 options held directly and 1,997,836 ordinary shares held indirectly, without altering the overall economic exposure to the company.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has reported a change in the interests of director German Arango following the lapse of certain equity incentives. On 23 December 2025, 53,520 nil-price options held directly by Arango lapsed after vesting conditions were not met, reducing his holding of those specific options while leaving his remaining option grants and substantial direct and indirect shareholdings in the company unchanged. The disclosure underscores the conditional nature of the director’s incentive arrangements but does not alter his overall significant equity exposure to ImExHS.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has reported a change in the holdings of non-executive director Carlos Jaime Palacio, who maintains both direct and indirect interests in the company’s fully paid ordinary shares and nil-price options through personal and family trust-related structures. The update shows Palacio received 26,802 new ordinary shares, valued at $10,080 and issued at $0.3761 per share, in lieu of director’s fees for the quarter ending 31 December 2025, increasing his direct shareholding to 352,244 shares; the transaction underscores the company’s continued use of equity-based remuneration for board members, aligning director incentives more closely with shareholder interests.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has disclosed a change in the interests of non-executive director Douglas Lingard, in line with ASX requirements. Lingard increased his direct holding by 26,802 fully paid ordinary shares, taking his direct stake to 326,764 shares, alongside existing nil-price options and substantial indirect holdings through related entities. The additional shares were issued in lieu of director fees for the quarter ending 31 December 2025, highlighting the company’s ongoing practice of compensating directors partly in equity, which aligns their interests more closely with shareholders and modestly increases director ownership in the company.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has reported a change in the interests of non-executive director Damian Banks, who has increased his direct holding in the company. The additional 26,802 fully paid ordinary shares were issued in lieu of director fees for the quarter ending 31 December 2025, lifting Banks’ direct shareholding while his indirect holding via a superannuation fund remains unchanged; the move further aligns the director’s remuneration with shareholder outcomes but does not involve any on-market trading or changes to contractual interests.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has disclosed a change in the interests of non-executive director Douglas Flynn, who has both direct and indirect holdings in the company’s fully paid ordinary shares and options through various nominee and investment entities. Flynn’s direct holding increased by 53,604 fully paid ordinary shares, taking his direct shareholding to 160,573 shares, following the issue of new shares in lieu of non-executive director fees for the quarter ending 31 December 2025, a move that modestly strengthens director equity alignment without involving any on-market trading or closed-period clearances.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has applied to the ASX for quotation of 134,010 new ordinary fully paid shares issued under an employee incentive scheme. The additional securities, to be quoted from 23 December 2025, modestly expand the company’s quoted share capital and reflect ongoing use of equity-based remuneration, with limited immediate impact expected on existing shareholders given the relatively small size of the issue.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.
ImExHS Limited has notified the market that a total of 363,947 unlisted options over its shares have lapsed, following the failure or incapacity of the conditions attached to those securities to be satisfied. The cessation covers three series of nil‑exercise‑price options, with expiry dates in 2033, 2034 and 2035, and slightly reduces the company’s pool of potential future equity dilution, clarifying its issued capital structure for existing shareholders.
The most recent analyst rating on (AU:IME) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on ImExHS Limited stock, see the AU:IME Stock Forecast page.